Almirall Signs Deal with Forest for COPD Therapy
By Business Review Editor
Pharma Deals Review: Vol 2006 Issue 71 (Table of Contents)
Published: 6 May-2006
DOI: 10.3833/pdr.v2006.i71.524 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
Almirall Prodesfarma entered into an agreement with Forest Laboratories Holdings to develop, market and distribute Almirall’s muscarinic antagonist LAS34273 for chronic obstructive pulmonary disease, asthma and bronchitis in US...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS